MAPT and Alzheimer disease: It is an orally available small molecule that crosses the BBB and was found to increase the levels of the neurotrophic factor progranulin (PGRN), reduce neuroinflammation and tau accumulation, and promote neuronal survival and synaptogenesis in preclinical models of AD and aging.